Thrombectomy Devices Market Report 2025

The thrombectomy devices market size has grown strongly in recent years. It will grow from $1.54 billion in 2024 to $1.65 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increased incidence of stroke, aging population and vascular disorders, advancements in minimally invasive procedures, awareness and early intervention, improved clinical outcomes.

The thrombectomy devices market size is expected to see strong growth in the next few years. It will grow to $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to expanding aging population, advances in thrombectomy technology, global initiatives for stroke awareness, integration with telemedicine, collaborations for research and development. Major trends in the forecast period include introduction of next-generation stent retrievers, focus on neurointerventional thrombectomy, integration of imaging guidance technologies, enhancements in thrombus detection and imaging, shift toward outpatient thrombectomy procedures.

The rising incidence of cardiovascular diseases is projected to drive the growth of the thrombectomy devices market in the coming years. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and arrhythmias. Thrombectomy is a procedure designed to remove blood clots that have formed in blood vessels, which is crucial in treating cardiovascular conditions like acute ischemic stroke and acute myocardial infarction (heart attack). Consequently, as the prevalence of cardiovascular diseases increases, so does the demand for thrombectomy devices. For example, in October 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that in 2022, heart disease claimed the lives of 702,880 individuals, accounting for 1 in every 5 deaths. Thus, the growing incidence of cardiovascular diseases is fueling the expansion of the thrombectomy devices market.

The growth of the thrombectomy devices market is further fueled by the increasing aging population. An aging population signifies a demographic shift marked by a growing proportion of elderly individuals within a society. Thrombectomy devices play a crucial role in addressing various health concerns prevalent in the aging population, including stroke, coronary artery disease, aortic thrombosis, deep vein thrombosis (DVT), and others. According to the World Health Organization's projections in October 2022, it is anticipated that by 2030, one out of every six individuals globally will be 60 years old or older. The proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion during this period. Furthermore, by 2050, the global population of individuals aged 60 and older is predicted to double, reaching 2.1 billion. Therefore, the increasing aging population is a significant driver for the growth of the thrombectomy devices market.

Technological advancements are a prominent trend gaining traction in the thrombectomy devices market. Companies within this market are embracing new technologies to maintain their competitive edge. For example, in February 2022, CERENOVUS, a US-based company specializing in neurovascular care and part of Johnson & Johnson Medical Devices Companies, introduced EMBOGUARD, a next-generation balloon guide catheter. This catheter is utilized in endovascular procedures, particularly for patients with acute ischemic stroke. EMBOGUARD is the latest addition to the CERENOVUS Stroke Solutions suite of technologies, designed for compatibility to assist physicians in performing mechanical thrombectomy procedures. The EMBOGUARD Balloon Guide Catheter aims to enhance clot clearance by regulating blood flow locally during mechanical thrombectomy operations. Balloon guide catheters contribute to improving first-pass recanalization, reducing procedure duration, and minimizing the risk of clot fragments breaking off and generating distant emboli.

Major players in the thrombectomy devices market are dedicated to creating innovative solutions, such as arterial thrombectomy systems. An arterial thrombectomy system is a medical device specifically crafted for removing blood clots (thrombi) from arteries. For instance, in June 2023, Penumbra, Inc., a US-based healthcare company, unveiled the 'Lightning Bolt 7,' a new arterial thrombectomy system designed for efficient blood clot removal from arteries. The system incorporates pressure sensors paired with an algorithm, facilitating the removal of large and fibrous blood clots from arteries with minimal blood loss. It is employed to address conditions where a blockage hinders blood flow to organs such as the intestines, spleen, limbs, and liver. The integration of computer-aided components not only enhances safety but also encourages a preference for an endovascular-first approach in a broader range of cases, prioritizing it over open surgery.

In May 2024, GTCR, a private equity firm based in the U.S., acquired Surmodics for an undisclosed amount. This acquisition is intended to bolster Surmodics' growth, support its innovation in medical technologies, enhance shareholder value, and utilize synergies to expand its market presence, while transitioning the company to a private structure for a more strategic focus. Surmodics specializes in drug delivery technologies, in vitro diagnostic (IVD) products, medical device coatings, and thrombectomy devices.

Major companies operating in the thrombectomy devices market include Stryker Corporation, Medtronic plc, Boston Scientific Corporation, Johnson and Johnson, Terumo Corporation, Penumbra Inc., Edwards Lifesciences Corporation, Argon Medical Devices Inc., Teleflex Incorporated, AngioDynamics, Koninklijke Philips NV, Spectranetics Corporation, Abbott Laboratories, Inari Medical Inc., C. R. Bard Inc., BTG International Ltd., Walk Vascular LLC, Phenox GmbH, Acandis GmbH & Co. KG, Straub Medical AG, MicroVention Inc., Vascular Solutions Inc., Rapid Medical, Endo International plc, Acrostak AG, Neuravi Limited, Control Medical Technology LLC, Kaneka Corporation, Arteria Therapeutics Inc., Baxter International.

North America was the largest region in the thrombectomy devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global thrombectomy devices market report during the forecast period. The regions covered in the thrombectomy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thrombectomy devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Thrombectomy devices are utilized for vacuum aspiration to eliminate occlusive clots in acute ischemic stroke. Surgical thrombectomy involves the extraction or suctioning out of the clot using a specially designed clot removal device introduced through a catheter, aiming to restore blood flow.

The primary types of thrombectomy devices include aspiration thrombectomy devices, mechanical thrombectomy devices, ultrasonic thrombectomy devices, and others. Aspiration thrombectomy devices are medical instruments designed for the removal of blood clots or thrombi from blood vessels. These devices find application in various areas such as cardiovascular, peripheral, and neurovascular applications, and are utilized by entities such as hospitals, surgical centers, ambulatory care facilities, academia, and contract research organizations (CROs).

The thrombectomy devices market research report is one of a series of new reports that provides thrombectomy devices market statistics, including thrombectomy devices industry global market size, regional shares, competitors with a thrombectomy devices market share, detailed thrombectomy devices market segments, market trends, and opportunities, and any further data you may need to thrive in the thrombectomy devices industry. This thrombectomy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thrombectomy devices market consists of sales of mechanical thrombectomy, and aspiration thrombectomy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.